مؤتمر
Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial
العنوان: | Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial |
---|---|
المؤلفون: | Armstrong, A. J., Clarke, Noel W, Thiery-Vuillemin, A., Oya, M., Procopio, G., De Menezes, J. J., Girotto, G. C., Ghatalia, P., Din, F. N. O., Spiegelhalder, P., Mincik, I., Van Alphen, R. J., Lumen, N., Hosius, C., Zhou, D. S., Barker, L., Dujka, M. E., Saad, F. |
المساهمون: | Duke University Medical Center, Durham, NC |
سنة النشر: | 2022 |
المجموعة: | The Christie School of Oncology: Christie Research Publications Repository |
نوع الوثيقة: | conference object |
اللغة: | English |
العلاقة: | https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5050Test; Armstrong AJ, Clarke NW, Thiery-Vuillemin A, Oya M, Procopio G, De Menezes JJ, et al. Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301470.; http://hdl.handle.net/10541/625805Test; Journal of Clinical Oncology |
DOI: | 10.1200/JCO.2022.40.16_suppl.5050 |
الإتاحة: | https://doi.org/10.1200/JCO.2022.40.16_suppl.5050Test http://hdl.handle.net/10541/625805Test |
رقم الانضمام: | edsbas.AC120190 |
قاعدة البيانات: | BASE |
DOI: | 10.1200/JCO.2022.40.16_suppl.5050 |
---|